Clinical trials: SCHIZOPHRENIA 1 (Disorder)
SCHIZOPHRENIA 1 (Disorder), Alcohol Use Disorder
Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia
The purpose of the study: obtaining knowledge about the impact of Snoezelen® therapy on the health of adults suffering from schizophrenia and requiring permanent institutional care, adults suffering from schizophrenia and adults…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Alcohol Use Disorder, Alcohol Dependence (Primary Condition)
- Trial name
- NCT07748078
- Testing
- Snoezelen® therapy for 6 weeks, Snoezelen® therapy for 12 weeks
- Where
- 2 sites in Poland
- Volunteers
- 140 people
- Sponsor
- The Jerzy Kukuczka Academy of Physical Education in Katowice
Psychosis
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
This is a safety study evaluating the subjects who participated in previous Organon trials of the drug Org 24448. Patients will undergo a Screening visit, 1 or 2 Evaluation visits, and a possible Follow-Up period.
- Trial name
- NCT00780585
- Testing
- SCH 900460
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia
This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths…
- Trial name
- QUARTZ (NCT06276361)
- Testing
- Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal
- Where
- Jordan
- Volunteers
- 58 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
Olanzapine is one of the most effective and best tolerated of the atypical antipsychotics, but it is also particularly associated with weight gain and metabolic problems.
- Trial name
- GWMD09126 (NCT01491490)
- Testing
- GWP42003 : GWP42004 (40:1)
- Where
- 6 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- GW Research Ltd
Psychosis, Schizophrenia
Virtual Reality Avatar Therapy for People Hearing Voices
Hearing voices is probably the worst form of acoustic hallucinations; which can be experienced as severely disturbing and is influenced by diverse factors including the ability of the individual to influence and control the…
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Hearing Voices When No One is Talking (Symptom)
- Trial name
- NCT04099940
- Testing
- Virtual Reality Avatar Therapy (VRAT), Assertiveness Training Program (ATP)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Psychiatric University Hospital, Zurich
SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia
This study is a confirmatory, double-blind, placebo-controlled randomized clinical trial (RCT) testing whether gamma EEG neurofeedback (EEG-NFB) improves working memory in adults with schizophrenia or schizoaffective disorder.
- Trial name
- NCT07592169
- Testing
- EEG Neurofeedback
- Volunteers
- 104 people
- Sponsor
- University of California, San Diego
SCHIZOPHRENIA 1 (Disorder)
The Effect of ACT-Based Nursing Interventions on Social Cognition, Emotion Regulation and Psychological Flexibility in Patients With Schizophrenia
This randomized controlled trial aims to evaluate the effect of Acceptance and Commitment Therapy (ACT)-based nursing interventions on social cognition, emotion regulation, and psychological flexibility in individuals diagnosed…
- Trial name
- NCT07661225
- Testing
- Acceptance and Commitment Therapy (ACT)-Based Nursing Intervention
- Volunteers
- 64 people
- Sponsor
- Ataturk University
Psychotic Disorder, Cognitive Function 1, Social
Social Cognition and Interaction Training for Adults With Psychotic Disorders: An Open Pilot Study in Finland
33 individuals with a psychotic disorder were given 22-24 sessions weekly or twice weekly of Social Cognition and Interaction Training (SCIT) and evaluated at the baseline and after the intervention.
- Trial name
- NCT02399020
- Testing
- Social Cognition and Interaction Training
- Where
- Finland
- Volunteers
- 33 people
- Sponsor
- Helsinki University Central Hospital
Psychosis
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis
The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to antipsychotic medications will it help maintain or improve cognitve functioning.
- Trial name
- NCT01720095
- Testing
- Niaspan
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Schizophrenia
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation (PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the treatment of patients with schizophrenia who…
- Trial name
- NCT01515423
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 174 sites in United States, Argentina and 24 more
- Volunteers
- 1,429 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of APN1125 when administered as single doses to healthy adult subjects.
- Trial name
- NCT02331433
- Testing
- APN1125
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- CoMentis
Tobacco Use Disorder
Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1
The purpose of this study is to test the use of High-Dose versus Regular-Dose Nicotine Patch for Nicotine Dependence in Individuals with Schizophrenia or Schizoaffective Disorder
- Trial name
- NCT00046813
- Testing
- Nicotine patch
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Clinical High Risk, Early Psychosis
Digital Strategies to Advance Help-Seeking Aim 1 and 2
This proposal aims to establish a Digital Laboratory focused on advancing help-seeking and expediting treatment initiation in youth ages 12-29 who are at Clinical High-Risk (CHR) for developing psychosis.
- Conditions
- Clinical High Risk, Early Psychosis, First Episode Psychosis
- Trial name
- NCT06774430
- Where
- United States
- Volunteers
- 25,000 people
- Sponsor
- Columbia University
Healthy
Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules
Commercial ziprasidone capsules show a large increase in bioavailability with food. The formulation tested in this study aims to reduce or eliminate that increase.
- Trial name
- NCT00821444
- Testing
- ziprasidone, B16 Fasted, B16 Fed
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Smoking Cessation
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.
- Trial name
- NCT00644969
- Testing
- varenicline (CP-526,555)
- Where
- 14 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Pfizer
Schizophrenia
A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia
The primary purpose is to evaluate the safety and tolerability of ASP6981 in participants with schizophrenia. Also primary purpose is to evaluate the pharmacodynamics of ASP6981 in participants with schizophrenia as measured by…
- Trial name
- NCT03356639
- Testing
- ASP6981
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Schizophrenia
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
The purpose of this study is to assess the safety, tolerability and PK profile of a single dose of 60mg RBO-7000 in stable subjects with schizophrenia who are on medication other than risperidone.
- Trial name
- NCT02765555
- Testing
- RBP-7000
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Indivior Inc.
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
This study investigates the ability of transcranial direct current stimulation (tDCS) applied over the motion processing area of the brain (area MT) to improve face emotion recognition (FER) ability.
- Trial name
- ButtomVP (NCT07469384)
- Testing
- transcranial direct current stimulation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
SCHIZOPHRENIA 1 (Disorder)
Multi-target TMS for Schizophrenia Negative Symptoms
This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left…
- Trial name
- NCT07559084
- Testing
- repetitive transcranial magnetic stimulation (rTMS)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shanghai Mental Health Center
Healthy
Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects
This Phase 1 study is the first clinical trial in Japanese subjects. The study is designed to evaluate the single- and multiple-dose pharmacokinetics, safety and tolerability of PF-03463275 oral controlled release formulation in…
- Trial name
- NCT01159626
- Testing
- PF-03463275
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer